



Canadian Leader 2012

Dr. Jan Oudenes Alphora Research Inc.

Combining keen industry insights, world class chemistry, and plain business smarts, Dr. Jan Oudenes' leadership over 8 years has secured Alphora's global recognition as a first in class producer of small molecule active pharmaceutical ingredients (API's). Having just completed a \$4M capital expansion, and hosting a dedicated, high quality staff of approximately 100, Alphora plans to further double its capacity through 2012-2013. Fred Haynes, Publisher.

Jan Oudenes has been a leader in the pharmaceutical and biotechnology CRO industry for three decades, developing the chemistry and manufacturing technology of small molecule active pharmaceutical ingredients (APIs). After completing academic studies in the Netherlands, Canada and Switzerland, Dr. Oudenes has been directly involved with the development of approximately 150 compounds for pre-clinical and clinical applications, as well as establishing manufacturing for newly commercialized products with an annual pharmacy retail value exceeding \$1 billion.

Starting his industrial career Dr. Oudenes joined a small start-up company as a research scientist, in the early eighties. Quickly rising through ranks as a scientist and leader, he

became President and CEO, growing the company into a leading and highly respected CRO.

As the outsourcing trend continued to increase with the consolidation of the Pharma sector and prevalence of smaller Biotechs, Dr. Oudenes founded Alphora Research in 2003. Alphora is a CRO that specializes in fundamental process chemistry research and technology development of small molecule APIs. Alphora's core focus is at the early stage of development, developing chemical processes and preparing materials for pre-clinical and clinical studies. As well, Alphora provides process chemistry expertise for later stage programs and niche commercial manufacturing.

Alphora helps their customers successfully advance lead candidates from the discovery mode, navigating through regulatory submissions for preclinical, IND, clinical trials and commercialization. Dr. Oudenes notes, "This is an area that was under served, especially with respect to the increased analytical requirements that have been under scrutiny from the regulatory agencies. Alphora works closely with its clients, generating a development strategy and phase appropriate road-map. We are like a consultant with a complete R&D lab and GMP scale-up operation."

Alphora's process chemistry development focused business model, as opposed to large scale manufacturing which is currently well served, has been quite successful. Over 8 years the company has been inspected and approved by the FDA, grown to 100 employees, operates 45,000 sq.ft. facilities that are equipped with state of the art synthetic and analytical laboratories, GMP Kilo Labs, GMP Pilot Plant and supporting QC/QA systems. A \$4M capital expansion project is wrapping up for 2011, which included a 50% increase to R&D, construction of a cytotoxics facility, and other additions to analytical and the GMP operations. The company also plans to double its Pilot Plant manufacturing capacity over 2012-2013.

"I am pleased with Alphora's initial success and the high quality results our team of dedicated staff continue to provide. I look forward to growing the organization further and working on new challenging projects."

Visit: www.alphoraresearch.com

